OrganiGram Holdings (TSE:OGI) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Organigram Holdings Inc. has announced promising preliminary results from a clinical study on its new FAST™ nanoemulsion technology, which offers a faster onset and improved bioavailability of cannabinoids for ingestible products. The technology is set to enhance Organigram’s product line, providing consumers with more control over their dosage experience. Final results of the study, which could significantly impact the adult-use cannabis market, are expected to be published later this year.
For further insights into TSE:OGI stock, check out TipRanks’ Stock Analysis page.